OBIO Opens 2019 Niagara Investment Summit, Connecting Canada’s Most Promising Innovations with Leading Global Investors
NIAGARA-ON-THE-LAKE, Ontario--(BUSINESS WIRE)-- OBIO (Ontario Bioscience Innovation Organization) is proud to announce the opening of the 2019 Niagara Investment Summit in Niagara-on-the-Lake, Ontario, on February 21-22, 2019.
The 2019 Niagara Investment Summit will feature over 30 of Canada’s most promising innovative health science companies meeting with more than 30 US and global investors and VCs in Niagara-on-the-Lake to propel investment in Canada’s health science industry.
“OBIO is excited by the enthusiastic reception of the 2019 Niagara Investment Summit by both the Canadian health science industry and the global investor community,” said Gail Garland, President and CEO of OBIO. “This year’s Summit will create the conditions for successful partnerships as OBIO continues to build an integrated health science economy in Ontario.”
Over two days in Niagara-on-the-Lake, the 2019 Niagara Investment Summit features Canada’s most promising innovative health science companies pitching to an audience of leading global investors, in addition to presentations from scientific and business experts as well as panel discussions on Scaling Canadian Health Science Companies and The State of Precision Medicine: Present & Future.
“The 2019 Niagara Investment Summit will provide health science companies a unique and powerful opportunity to meet with and present to leading global investors,” said Dr. Jeremy Bridge-Cook, CEO of Rna Diagnostics and Chair of OBIO’s Board of Directors. “This Summit also represents an opportunity for the Canadian health science industry more broadly. I am happy to be a part of the 2019 Niagara Investment Summit and I would like to congratulate OBIO on delivering an event of unsurpassed quality that will build Canada’s health science industry.”
The 2019 Niagara Investment Summit is supported by our sponsors – Norton Rose Fulbright, Amgen, the Cardiac Arrythmia Network of Canada (CANet) and Ontario Genomics – and partners - Centre for the Commercialization of Antibodies and Biologics (CCAB), McMaster University, Ontario Institute for Regenerative Medicine (OIRM), Ontario Brain Institute (OBI), Ryerson University Biomedical Zone, the University of Toronto, the University of Waterloo, Velocity and the Waterloo Institute for Nanotechnology.
The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health technologies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.
For more information please visit www.obio.ca and follow OBIO on Twitter @OBIOscience.
Director, Public Affairs and Communications